Get the Stockscreener App
11.42
7.23%
-0.89
After Hours:
10.50
-0.92
-8.06%
Xencor Inc stock is traded at $11.42, with a volume of 846.00K.
It is down -7.23% in the last 24 hours and down -10.57% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$12.31
Open:
$12.17
24h Volume:
846.00K
Relative Volume:
1.14
Market Cap:
$837.53M
Revenue:
$125.58M
Net Income/Loss:
$-92.14M
P/E Ratio:
-9.1919
EPS:
-1.2424
Net Cash Flow:
$-138.27M
1W Performance:
-5.85%
1M Performance:
-10.57%
6M Performance:
-1.30%
1Y Performance:
-0.78%
1-Day Range:
$11.27
$12.40
1-Week Range:
$11.04
$12.82
52-Week Range:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
11.42 | 837.53M | 125.58M | -92.14M | -138.27M | -1.2424 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Pharma News: What is the target price for Xencor Inc stock2026 Geopolitical Influence & Reliable Intraday Trade Plans - baoquankhu1.vn
Portfolio Recap: What is the long term forecast for Xencor Inc stockMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Investment Recap: Should you buy the dip on Xencor Inc2026 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Xencor Inc disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Vanguard (XNCR) reports 0 shares after internal realignment amendment - Stock Titan
Aug Levels: Is Xencor Inc stock showing strong momentumMarket Performance Report & Verified Technical Signals - baoquankhu1.vn
Buyout Rumor: Is Xencor Inc a top pick in the sectorMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Earnings Beat: Is Xencor Inc stock a good pick for beginnersWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Aug Sentiment: Should value investors consider Xencor Inc2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Shares Gap DownTime to Sell? - MarketBeat
JPMorgan Chase & Co. Reiterates Neutral Rating for Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock downgraded to neutral at JPMorgan on execution concerns By Investing.com - Investing.com Australia
JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18 - marketscreener.com
Xencor stock downgraded to neutral at JPMorgan on execution concerns - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving AverageHere's What Happened - MarketBeat
JP Morgan Downgrades Xencor (XNCR) - msn.com
How Xencor Inc. (XNCR) Affects Rotational Strategy Timing - Stock Traders Daily
XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Upgrade: What is the Moat Score of Xencor Inc2026 Selloffs & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Retail Trends: Can Xencor Inc beat the S P 500Quarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Earnings Recap: Is Xencor Inc backed by strong institutional buying2026 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Braidwell LP Lowers Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - The Globe and Mail
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans By Investing.com - Investing.com South Africa
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor, Genentech to End Protein Therapeutics Collaboration - TipRanks
Xencor (XNCR) SVP and general counsel sells 5,011 shares for RSU tax - Stock Titan
Xencor (XNCR) CFO sells 2,517 shares to cover RSU tax withholding - Stock Titan
Xencor (XNCR) CEO sells 21,476 shares to cover RSU tax obligations - Stock Titan
Genentech ends Xencor (NASDAQ: XNCR) efbalropendekin alfa license deal - Stock Titan
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):